Key facts, as of
As of November 6, 2026, Revvity Inc. (RVTY) trades at $155.11, up 73.3% over the past year. Its 52-week range runs from $81.22 to $171.74; the price is 9.7% below that high. It is 23.7% below its all-time high of $203.16, reached in December 2021. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +217.2%, against +316.3% for the S&P 500 (SPY). It sits 37.4% above its 200-day average of $112.91, and its 50-day average is above the 200-day too: an uptrend on both averages. Its 30-day volatility is 45.9% annualized, which we rate high risk. It has a trailing P/E of 68.9 and a dividend yield of 0.18%.
Cite: Portfolio Terminal, "Revvity Inc. (RVTY) stock analysis", 2026-11-06. https://portfolio-terminal.com/analyse/rvty
Where it trades today
trading 82% of the way up its 52-week range
How the price has moved
How far it is from its record
Revvity Inc. (RVTY) is 23.7% below its all-time high of $203.16, reached in December 2021. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +217.2%, against +316.3% for the S&P 500 (SPY).
The read, from its own figures
What its numbers say
- RVTY closes above its 50-day average ($147.52), and the 50-day sits above the 200-day ($112.91): on both averages the chart reads as an uptrend.
- At $155.11, RVTY is 9.7% below its 1-year high of $171.74, set on November 3, 2026, and 91.0% above its 1-year low of $81.22 (April 29, 2026).
- Over the past month RVTY rose 1.9%, from $152.16 to $155.11.
- RVTY trades at 68.9x its last twelve months of earnings and 26.0x the next twelve months' estimate, so analysts expect earnings 164.9% higher.
- Its P/E is 88.1% above the 36.6x median of the 3 other diagnostics & research companies we track (TMO, DHR, A).
- RVTY's 30-day volatility, 45.9% a year, works out to a typical daily move of about 2.9%.
- Yahoo Finance puts its beta at 1.09: over five years of monthly returns, RVTY moved about 1.09% for each 1% move of the S&P 500.
What would change the read
- A close under the 50-day average, $147.52 (−4.9% from the last close), would turn the read to a pullback; under the 200-day, $112.91 (−27.2%), the longer rise is in question.
- A close above $171.74 (+10.7%) would be a new 1-year high; below $81.22 (−47.6%), a new 1-year low.
How it is computed
- Prices are Yahoo Finance's daily candles for RVTY, the same ones the chart below draws; the P/E, forward P/E and beta are Yahoo Finance quote fields.
- The averages are simple means of the last 50 and 200 closes; the 1-year high and low are the highest high and lowest low of the last 252 sessions; the 30-day volatility is the standard deviation of the past month's daily returns, annualized with the square root of 252.
- Peers are the other companies Yahoo Finance files under diagnostics & research among the assets we track, not a full industry screen; the median counts those with a positive P/E.
- Every sentence here is written by code from those figures, refreshed daily; nobody edits it for RVTY by hand. It describes what the price and the multiples have done, not what they will do, and it is not advice.
Sources
- Yahoo Finance quote and daily historyopen →
The candles, the averages' inputs and the quote fields used for RVTY. Last refresh: Nov 8, 2026, 10:53 PM UTC.
- How Portfolio Terminal computes its figuresopen →
The methodology page behind the analytics and their refresh cadence.
- Industry classification
Yahoo Finance's industry, as stored in our list of tracked assets: Diagnostics & Research.
What Revvity Inc. does
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, and training and services; and instruments, reagents, and assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. It also develops technologies that enable…
What analysts expect
RVTY carries a buy consensus from 15 analysts, with an average price target of $171.07 versus $155.11 today (+10.3%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
RVTY generated $2.94B in trailing revenue (4.3% year over year), with a 8.6% net margin, and $626.77M of free cash flow, against $2.17B of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $2.86B | $1.56B | $356.63M | $241.20M | $2.07 | $509.41M |
| 2024 | $2.76B | $1.54B | $346.74M | $270.38M | $2.24 | $541.65M |
| 2023 | $2.75B | $1.54B | $300.56M | $693.09M | $5.56 | $9.90M |
| 2022 | $3.31B | $1.99B | $742.70M | $569.18M | $4.59 | $594.18M |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
Which ETFs hold it
RVTY is in 11 of the 54 ETFs we track. It weighs most in XLV: 0.27% of the fund, holding #50 of 62.
How its figures compare with those peers
Companies in the same industry
RVTY beside the other companies Yahoo Finance files under diagnostics & research among the assets we track (TMO, DHR, A, largest first).
RVTYyou are here$155.11$17.31B
TMOThermo Fisher Scientific$694.76$257.42BDHDHRDanaher Corporation$230.25$161.99B
AAgilent Technologies$174.76$49.28BWhat the chart is saying
In an uptrend, 9.7% under its 1-year high with no resistance above.
uptrend- Price is 5.1% above its 50-day average and 37.4% above its 200-day.
- RSI at 51 is neither stretched nor washed out.
- Nothing above has stopped it this year; the nearest floor is $116.30 (-25.0%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
How is RVTY valued right now?
Revvity Inc. trades at 68.9 times its last twelve months of earnings and 26.0 times the next twelve months' estimate (Yahoo Finance, November 6, 2026). On the chart: in an uptrend, 9.7% under its 1-year high with no resistance above. Price is 5.1% above its 50-day average and 37.4% above its 200-day.
What is the risk level of RVTY?
Based on 30-day volatility of 45.9%, RVTY has HIGH risk. Its beta of 1.09 means it has swung more than the S&P 500 over the last five years.
Does RVTY pay dividends?
Yes, Revvity Inc. has a dividend yield of 0.18%.
How far is RVTY from its all-time high?
Revvity Inc. is 23.7% below its all-time high of $203.16, reached in December 2021. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +217.2%, against +316.3% for the S&P 500 (SPY).
Which ETFs hold RVTY?
11 of the 54 popular ETFs we track hold Revvity Inc.. The largest weights: XLV (0.27%), RSP (0.25%), VB (0.22%), CSPX (0.03%) and VOO (0.03%). Measured on each issuer's full holdings file, dated September 30 to October 18, 2026.
How much of VOO is RVTY?
0.03%, as of September 30, 2026: RVTY is holding #403 of 505 in Vanguard's file for VOO. $1,000 in VOO puts about $0.26 in Revvity Inc..
What is the analyst price target for RVTY?
The average analyst price target for Revvity Inc. (RVTY) is $171.07 based on 15 analyst estimates, about 10.3% above the current price of $155.11. The published range runs from $122.00 to $200.00.
How much revenue does RVTY generate?
Revvity Inc. reported $2.94B in trailing twelve-month revenue. Revenue growth is running at 4.3% year over year. Net margin sits at 8.6%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare RVTY with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.